YubNub Social

3 yrs

"I would believe if I were able, but I'm eating from the crumbs from your table" - U2

Comment

changed her profile picture

3 yrs

Comment

Welcome to YubNub!

· Reply · 1629337877

Thanks

· 1629338475

1 Reply

Welcome !

· Reply · 1629380229

3 yrs

Why isn't mainstream news reporting this?https://www.jpost.com/health-s....cience/covid-90-perc

www.jpost.com

COVID: 90% of patients treated with new Israeli drug discharged in 5 days - The Jerusalem Post

The Phase II trial for an Israeli COVID drug saw some 29 out of 30 patients, moderate to serious, recover within days.

Comment

3 yrs

I knew better all along than to believe we need to raise a dehumanized generation that will never see any smiles or frowns. https://www.peoplespunditdaily.....com/policy/2021/05/

Study: Mask-Mandates and Use Not Associated With Lower Covid-19 Case Growth | People's Pundit Daily

www.peoplespunditdaily.com

Study: Mask-Mandates and Use Not Associated With Lower Covid-19 Case Growth | People's Pundit Daily

The first ecological study finds mask mandates were not effective at slowing the spread of coronavirus (Covid-19) in U.S. states, meaning they did not work.

Comment

3 yrs

How do these guys get away with mandates on drugs that aren't licensed when the FDA code says that it has to be voluntary?

https://www.law.cornell.edu/us....code/text/21/360bbb-

21 U.S. Code § 360bbb–3 - Authorization for medical products for use in emergencies | U.S. Code | US Law | LII / Legal Information Institute

www.law.cornell.edu

21 U.S. Code § 360bbb–3 - Authorization for medical products for use in emergencies | U.S. Code | US Law | LII / Legal Information Institute

Comment

And paragraph (3) below-- we already know that hydroxychloroquine and Ivermectin have been approved and in use for quite some time for other things, and has been proven effective in preventing/treating COVID-19:

(2) that, based on the totality of scientific evidence available to the Secretary, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that—

(A) the product may be effective in diagnosing, treating, or preventing—

(i) such disease or condition; or

(ii) a serious or life-threatening disease or condition caused by a product authorized under this section, approved or cleared under this chapter, or licensed under section 351 of the Public Health Service Act [42 U.S.C. 262], for diagnosing, treating, or preventing such a disease or condition caused by such an agent; and

( the known and potential benefits of the product, when used to diagnose, prevent, or treat such disease or condition, outweigh the known and potential risks of the product, taking into consideration the material threat posed by the agent or agents identified in a declaration under subsection (b)(1)(D), if applicable;

(3) that there is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating such disease or condition;

· Reply · 1629334681

And paragraph (3) below-- we already know that hydroxychloroquine and Ivermectin have been approved and in use for quite some time for other things, and has been proven effective in preventing/treating COVID-19:  
 
(2) that, based on the totality of scientific evidence available to the Secretary, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that— 
 
(A) the product may be effective in diagnosing, treating, or preventing— 
 
(i) such disease or condition; or 
 
(ii) a serious or life-threatening disease or condition caused by a product authorized under this section, approved or cleared under this chapter, or licensed under section 351 of the Public Health Service Act [42 U.S.C. 262], for diagnosing, treating, or preventing such a disease or condition caused by such an agent; and 
 
(B) the known and potential benefits of the product, when used to diagnose, prevent, or treat such disease or condition, outweigh the known and potential risks of the product, taking into consideration the material threat posed by the agent or agents identified in a declaration under subsection (b)(1)(D), if applicable; 
 
(3) that there is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating such disease or condition;